Drugs / GC304
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05860569 | Sep 2024 → Dec 2026 expected | inherited lipid metabolism disorder | GeneCradle Inc | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GC304 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05860569 ↗ |
| Route | Intravenous | “GC304 will be administrated intravenously.” NCT05860569 ↗ |